ERBB2 and breast carcinoma: Gates et al. used HLA II molecules with HER2/neu peptide (AE37) vaccine treatment on breast cancer patients and found that the number of peripheral blood lymphocytes CD4+CD25+Foxp3+Tregs decreased in the patients [42].